Zealand Pharma President of US Operations on first launch: Timing was our most important goal

Zealand Pharma has started to launch its hypoglycemia treatment Zegalogue in the US. According to the president of the firm's US operations, this is a crucial time as Americans start returning to schools and the covid-19 pandemic has led the company to invest significantly in digital sales and promotion opportunites.
Zealand Pharma President of US Operations Frank Sanders | Photo: Zealand Pharma / PR
Zealand Pharma President of US Operations Frank Sanders | Photo: Zealand Pharma / PR
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN

By launching low blood sugar treatment Zegalogue on the US market, Zealand Pharma is marking its transition from development company to commercial biotech company. Although it was established in 1998, the firm had never sent its own drug to market until last week.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading